EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study

Caecilia S E Doorenbos iD, Yvonne van der Veen, Adrian Post, Jip Jonker, Tim J Knobbe, Daan Kremer iD, Dion Groothof iD, M Rebecca Heiner-Fokkema, Christa A Koops, Klaas Bijsterveld, Erik Marsman, Ietje T Hazenberg und 8 weitere

PLOS One · 05.08.2026 · 21 (8) · e0354883

DOI: 10.1371/journal.pone.0354883 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 05.08.2026. Verfasst von Caecilia S E Doorenbos und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Groningen, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Renal Dialysis, Creatine, Dietary Supplements. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crearene AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients receiving hemodialysis are at risk of creatine deficiency due to impaired endogenous synthesis and losses during dialysis. Creatine deficiency is associated with lower health-related quality of life and higher mortality. We investigated the feasibility, tolerability and safety of intradialytic creatine supplementation during hemodialysis.

Methods

In this double-blind, randomized, placebo-controlled pilot study (ClinicalTrials.gov ID: NCT05148208), 16 hemodialysis patients were included into four sequentially initiated groups, with each group receiving a fixed creatine concentration in the dialysate (0.5 mmol/L, 1.0 mmol/L, 1.5 mmol/L and 2.0 mmol/L, respectively), with block randomization in a 3:1 ratio (creatine:placebo) per group. Dropouts were replaced. Intra-dialytic creatine was administered during a 6-week period. Primary outcomes were changes in pre-dialytic intra-erythrocytic and plasma creatine concentrations, which were analyzed with linear mixed models.

Results

16 hemodialysis patients (aged 27–78 years, 9 female) completed the study. Creatine supplementation was generally well tolerated. One patient receiving 1.5 mmol/L creatine dropped out due to a potential side effect. No serious adverse events occurred. The median (minimum-maximum) baseline pre-dialytic intra-erythrocytic and plasma creatine concentrations were 963 (407–1822) and 35 (13–287) µmol/L, respectively. At 6 weeks, the changes in pre-dialytic intra-erythrocytic creatine concentration compared to placebo (95% CI) were +399 (−269, 1066), + 685 (+17, + 1352), + 1146 (+431, + 1766) and +1098 (+431, + 1766) µmol/L for the increasing dosage treatment groups respectively (overall treatment effect p < 0.001). The changes in pre-dialytic plasma creatine concentration compared to placebo were −16 (−301, + 270), + 21 (−264, + 307), + 119 (−264, + 307) and +163 (−122, + 449) µmol/L for the increasing dosage treatment groups respectively (overall treatment effect p = 0.002).

Conclusion

Intra-dialytic creatine supplementation is a feasible, safe, well-tolerated method to increase circulating creatine concentrations in patients treated with hemodialysis. These findings support the rationale for a larger randomized controlled trial to investigate its potential to improve health-related quality of life and reduce mortality risk in this population. Trial Registration: ClinicalTrials.gov ID NCT05148208, date of first registration 08/12/2021

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisCreatineDietary SupplementsHumansFemaleMiddle AgedDouble-Blind MethodPilot ProjectsAdultMaleAgedFeasibility StudiesQuality of Life

Substanzen

Creatine

Autor:innen und Institutionen

  • University of Groningen, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
  • University of Groningen, Department of Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands.
  • Dialysis Center Groningen, Groningen, The Netherlands.
  • University of Groningen, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Biology, ETH Zurich, Zurich, Switzerland.

ORCID-Profile: Caecilia S E Doorenbos, Daan Kremer, Dion Groothof, Stephan J L Bakker

Förderung

  • Crearene AG

Zitieren

APA

Doorenbos, C. S. E., van der Veen, Y., Post, A., Jonker, J., Knobbe, T. J., Kremer, D., Groothof, D., Heiner-Fokkema, M. R., Koops, C. A., Bijsterveld, K., Marsman, E., Hazenberg, I. T., Manson, N. A., Appeldoorn, T. Y. J., Boersma, H. H., Dekkers, B. G. J., Touw, D. J., Wallimann, T., Franssen, C. F. M., & Bakker, S. J. L. (2026). Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study. PLOS One, 21(8), e0354883. https://doi.org/10.1371/journal.pone.0354883

Vancouver

Doorenbos CSE, van der Veen Y, Post A, Jonker J, Knobbe TJ, Kremer D, et al. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study. PLOS One. 2026;21(8):e0354883. doi:10.1371/journal.pone.0354883

BibTeX
@article{Doorenbos2026,
  author = {Doorenbos, Caecilia S E and van der Veen, Yvonne and Post, Adrian and Jonker, Jip and Knobbe, Tim J and Kremer, Daan and Groothof, Dion and Heiner-Fokkema, M Rebecca and Koops, Christa A and Bijsterveld, Klaas and Marsman, Erik and Hazenberg, Ietje T and Manson, Nienke A and Appeldoorn, Theo Y J and Boersma, Hendrikus H and Dekkers, Bart G J and Touw, Daan J and Wallimann, Theo and Franssen, Casper F M and Bakker, Stephan J L},
  title = {Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {8},
  pages = {e0354883},
  doi = {10.1371/journal.pone.0354883}
}
Kostenlos starten →